Logo
Amplia Therapeutics Limited

Amplia Receives R&D Tax Rebate Totalling $4.78 Million

Amplia Therapeutics Limited (ASX: ATX) has received A$4,778,235.52 through the Australian Government’s Research and Development Tax Incentive for the financial year ended 31 March 2026. 

The Research and Development Tax Incentive encourages eligible Australian businesses to undertake research and development activities by providing a refundable tax offset for qualifying expenditure. 

Amplia’s rebate relates to expenditure on research and development activities associated with its FAK inhibitor programs, narmafotinib (AMP945) and AMP886. These activities are primarily related to the Company’s ongoing clinical trials of narmafotinib in patients with advanced pancreatic cancer. 

The funds will support: 

  • further progression of the ACCENT and AMPLICITY clinical trials of narmafotinib 

  • the ACCENT-MINI Trial 

  • the PRROSE Study 

  • the Lilly combination study 

  • additional supporting research and development activities 

Click Here to Read the ASX Announcement

Share your feedback

Discover